TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9164318
Drug: Highly active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly active antiretroviral treatment (HAART) regimens
Study: 3667007
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline suspension
Study: 3667007
Drug: Slow-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release theophylline tablets
Study: 25523492
Drug: Inhalation sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation sedation with nitrous oxide/oxygen (N2O/O2)
Study: 21953275
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg) taken with food
Study: 21953275
Drug: Selumetinib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (75 mg) taken after fasting for at least 10 hours
Study: 10509320
Drug: Primary combined‐modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary combined‐modality therapy
Study: 10509320
Drug: Preoperative combined‐modality
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative combined‐modality therapy
Study: 10509320
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of radiation (INT 0123 trial)
Study: 21816056
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination (Bifidobacterium infantis, Streptococcus thermophilus and Bifidobacterium lactis)
Study: 9385482
Drug: Sparfloxacin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 400 mg orally once followed by 200 mg orally daily for 10 days (n = 168)
Study: 9385482
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg orally every 8 hours for 10 days (n = 162)
Study: 7961014
Drug: Continuous low
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous low dose rate iridium implants following 50 Gy whole breast irradiation
Study: 7961014
Drug: Dose rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose rate (mean 0.57, range 0.26-0.89 Gy/h)
Study: 27746539
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg intrathecal levobupivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of levobupivacaine 0.125% with fentanyl 30 μg
Study: 27746539
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg intrathecal ropivacaine with 25 μg fentanyl followed by epidural top‐ups of 14 ml of ropivacaine 0.2% with fentanyl 30 μg
Study: 23908479
Drug: Heat-treated zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-treated zoster vaccine (ZVHT)
Study: 10950766
Drug: Saquinavir soft-gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir soft-gel capsules (SQVsgc)
Study: 10950766
Drug: Saquinavir hard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saquinavir hard capsules (SQVhc)
Study: 8979093
Drug: No antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antihypertensive therapy
Study: 1468245
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks
Study: 1468245
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium hyaluronate in 2 ml phosphate buffer for 5 weeks + 0.4 mg dexamethasone phosphate
Study: 373254
Drug: Tagamet (cimetidine)
Normalized name: cimetidine Oral Tablet [Tagamet]
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tagamet (cimetidine) 1 g daily (3x200 mg after meal and 400 mg in the evening) for 20 days
Study: 7877646
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy (cyclophosphamide, methotrexate, and fluorouracil) for 12 monthly cycles
Study: 2172161
Drug: Benazepril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benazepril (20 mg once or 5 mg four times at 6-hour intervals)
Study: 23818692
Drug: 1.36 g
Normalized name: FERROUS SULFATE 381.36 g in 454 g TOPICAL POWDER [Blood Stop Powder]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.36 g L-carnitine + 80 g carbohydrate (Carnitine)
Study: 23818692
Drug: 80 g
Normalized name: PEG-80 GLYCERYL COCOATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 g carbohydrate (Control)
Study: 18822917
Drug: Conventional liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional liver protecting therapy (Control)
Study: 12950604
Drug: High-dose dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dual therapy (omeprazole 4 x 40 mg and amoxicillin 4 x 750 mg for 14 days)
Study: 12950604
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (omeprazole 2 x 20 mg, bismuthcitrate 4 x 107 mg, metronidazole 4 x 500 mg and tetracycline 4 x 500 mg for 14 days)
Study: 8829931
Drug: Nasal inhalation
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal inhalation of sevoflurane 5%
Study: 8829931
Drug: Oral inhalation
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation of sevoflurane 5%
Study: 2068468
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg) plus aztreonam (1 g)
Study: 2068468
Drug: Clindamycin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (600 mg) plus gentamicin (80 mg)
Study: 7048482
Drug: Aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin + Dipyridamole
Study: 31286694
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow (NHF) at 2, 4, and 6 L/min
Study: 26022434
Drug: RCA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCA plus low-dose dalteparin
Study: 26022434
Drug: Normal-dose dalteparin
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-dose dalteparin
Study: 26022434
Drug: RCA only,
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCA only, Normal-dose dalteparin
Study: 17478880
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied heparin spraygel
Study: 17478880
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (peroral analgesics or nonsteroidal anti‐inflammatory drugs, elastic stockings, mild ambulation)
Study: 12815777
Drug: Mivacron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacron (0.15 mg/kg)
Study: 12815777
Drug: Mivacron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacron (0.1 mg/kg)
Study: 9274466
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g four times daily
Study: 9274466
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g twice daily
Study: 8391041
Drug: Post-therapy liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-therapy liver biopsy
Study: 24262498
Drug: Polidocanol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polidocanol (1, 3, or 4 ml depending on hydrocele size) after aspiration
Study: 22313070
Drug: lignocaine added
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: lignocaine added to infiltrating solution
Study: 20089522
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate (3.75 mg, depot i.m. injection, every 4 weeks)
Study: 18453852
Drug: Lopinavir/ritonavir tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir tablets (600/150 mg or 800/200 mg twice daily) with 600 mg rifampicin once daily
Study: 15753741
Drug: 4 ng/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ng/kg intravenous Escherichia coli endotoxin
Study: 7437237
Drug: Indoramin 75
Normalized name: indoramin
DrugBank: Indoramin (DB08950)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 75 mg twice daily
Study: 12165596
Drug: Oral 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 30% glucose (0.3 mL)
Study: 12165596
Drug: Placebo (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.3 mL of sterile water)
Study: 12165596
Drug: Oral 30%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 30% glucose (0.3 mL) plus pacifier
Study: 6760120
Drug: Both types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both types of insulin therapy
Study: 31701593
Drug: Minimally interrupted
Normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally interrupted direct oral anticoagulation (DOAC) therapy
Study: 31701593
Drug: Uninterrupted direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uninterrupted direct oral anticoagulation (DOAC) therapy
Study: 27317706
Drug: Sumatriptan (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (6 mg s.c. injection)
Study: 22709272
Drug: 5% nicotinamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% nicotinamide lotion
Study: 22709272
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral nicotinamide
Study: 15732070
Drug: Fluoxetine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine with guided self-help
Study: 15732070
Drug: Fluoxetine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine without guided self-help
Study: 7594660
Drug: Ro 24-7429
Normalized name: Ro 24-7429
DrugBank: Ro 24-7429 (DB16062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 24-7429 (Tat antagonist) at 75, 150, or 300 mg/day
Study: 314399
Drug: Enelbin‐Rheuma‐ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enelbin‐Rheuma‐ointment
Study: 30169322
Drug: Low-exposure everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Low-exposure everolimus (3-7 ng/mL)
Study: 30169322
Drug: High-exposure everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-exposure everolimus (9-15 ng/mL)
Study: 30169322
Drug: Everolimus (3-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (3-15 ng/mL) during extension phase
Study: 27694157
Drug: Topotecan (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.5 mg/m2 intravenously or 2.3 mg/m2 orally, daily for 5 days for 4 cycles)
Study: 27694157
Drug: Linsitinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib (150 mg orally twice daily until progression)
Study: 19086108
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with oestradiol and noretisterone acetate, vitamin D3 and calcium
Study: 12600843
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g high-performance inulin/d
Study: 8407216
Drug: Levodopa/carbidopa 25/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 25/6.25 mg
Study: 8407216
Drug: Levodopa/carbidopa 50/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa 50/12.5 mg
Study: 3940504
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (300 mg orally) with zinc sulfate
Study: 3940504
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (30 mL orally) with zinc sulfate
Study: 27602929
Drug: Self-prepared, 1-day,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-prepared, 1-day, low-residue diets with a same-day 2.0-L single-dose of polyethylene glycol (Group A)
Study: 27602929
Drug: Prepackaged low-residue
Normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepackaged low-residue diets plus 2.0 L of polyethylene glycol (Group B)
Study: 27602929
Drug: Prepackaged low-residue
Normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prepackaged low-residue diets plus 1.5 L of polyethylene glycol (Group C)
Study: 23506436
Drug: Ice slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice slurry ingestion (10 g · kgBM(‐1) of ice slurry < 1°C)
Study: 9275430
Drug: Tumor infiltrating
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor infiltrating lymphocytes (TIL) and chemotherapy
Study: 29995356
Drug: Withania somnifera
Normalized name: WITHANIA SOMNIFERA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withania somnifera extract (WSE) 1,000 mg/d
Study: 27580669
Drug: Physiotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy and Occupational Therapy (PT and OT) NHS services, n=381
Study: 27580669
Drug: No therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy, n=381
Study: 20142595
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous pegfilgrastim injection (100 microg/kg)
Study: 20142595
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous filgrastim administration (5 microg/kg)
Study: 16563271
Drug: Xuezhikang (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (0.6 g, Bid)
Study: 12372764
Drug: DDAVP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP + low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Study: 12372764
Drug: Low-calcium diet
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium diet (approximately 500 mg/day) for 3-6 months in hypercalciuric patients
Study: 1431364
Drug: Cefepime (CFPM)
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime (CFPM) 1.0 g twice daily for 14 days
Study: 1431364
Drug: Ceftazidime (CAZ)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (CAZ) 1.0 g twice daily for 14 days
Study: 20921836
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type-A (BTX-A) injection
Study: 20921836
Drug: Control drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug (NaCl 0.9% or bupivacaine 0.25%)
Study: 16083067
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose MNZ (2 g daily for 7 days)
Study: 16083067
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg N‐9 vaginal suppository daily for 7 days
Study: 16083067
Drug: Conventional MNZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional MNZ dose (1 g daily for 7 days) plus 100 mg N‐9 suppository for 7 days
Study: 9316695
Drug: L-DOPA (LD)
Normalized name: α-methyl-L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-DOPA (LD) treatment
Study: 3354990
Drug: Indomethacin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (25 mg four times a day for 7 doses)
Study: 29327644
Drug: PREHAB+ (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREHAB+ (once weekly supervised prehabilitation)
Study: 27064347
Drug: Body Psychotherapy/Dance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body Psychotherapy/Dance Movement Therapy (BPT/DMT) - 20 sessions
Study: 22938573
Drug: 6 mm
Normalized name: I-Port, 6 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mm implants
Study: 22938573
Drug: 11 mm
Normalized name: Interleukin 11
DrugBank: Oprelvekin (DB00038)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 11 mm implants
Study: 20031783
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical therapy
Study: 10944126
Drug: LV5FU2 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 plus oxaliplatin (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks, plus 85 mg/m2 oxaliplatin on day 1)
Study: 10944126
Drug: LV5FU2 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 alone (200 mg/m2/d leucovorin, 400 mg/m2/d bolus 5FU, 600 mg/m2/d infusional 5FU for 2 days every 2 weeks)
Study: 8746336
Drug: Topical calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcitriol (1.5 micrograms per day, 15 micrograms/g of Vaseline)
Study: 8746336
Drug: Topical calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcitriol ointment (15 micrograms/g Vaseline) applied to all lesions (up to 10 g, 150 micrograms calcitriol)
Study: 20510549
Drug: Heroin Assisted
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin Assisted Treatment (HAT)
Study: 20510549
Drug: Optimized Methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized Methadone Maintenance Treatment (MMT)
Study: 8543957
Drug: Manufacturer and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufacturer and brand of L-tryptophan
Study: 1791086
Drug: Single-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose verapamil (120 mg)
Study: 1791086
Drug: Seven-doses of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-doses of verapamil (120 mg thrice daily)
Study: 6780258
Drug: Nitroglycerin (NTG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NTG) treatment for 48 hours
Study: 25623343
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy for insomnia (CBT-I), 8 sessions
Study: 10783015
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) during acute diarrhea
Study: 10783015
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg of retinol as retinyl palmitate) after resolution of diarrhea
Study: 8803503
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 g, administered 2 hours before and after 20 km of the marathon)
Study: 1615614
Drug: Doxorubicin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (20 mg/m2 body surface area)
Study: 6235140
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg twice daily
Study: 6235140
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) 1 g/wk intramuscularly
Study: 6235140
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (TAM and MPA)
Study: 18962989
Drug: EPA 2
Normalized name: docosahexaenoic acid/epa 250 mg-100 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA 2 g/day
Study: 4054194
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.d. (twice daily)
Study: 30135541
Drug: Iterative model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iterative model reconstruction (IMR) with 80 kV/30 ml contrast media
Study: 30135541
Drug: Filtered back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filtered back projection (FBP) with 100 kV/50 ml contrast media
Study: 25363127
Drug: triamcinolone 0.5
Normalized name: triamcinolone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: triamcinolone 0.5 mL with lidocaine 2%
Study: 20375984
Drug: SBR759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759 at 11.25 g/day
Study: 20375984
Drug: SBR759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759 at 15.0 g/day
Study: 20375984
Drug: SBR759 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBR759 at 3.75-15 g/day
Study: 18599797
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily
Study: 18599797
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens 0.625 mg daily
Study: 12887173
Drug: Duac Topical
Normalized name: Duac Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duac Topical Gel (clindamycin 1%‐benzoyl peroxide 5%)
Study: 1299794
Drug: glucose solution
Normalized name: TrueControl Glucose Solution Level 0
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glucose solution (placebo)
Study: 30811685
Drug: High postural
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High postural sway (highest quartile of ML sway)
Study: 30811685
Drug: High postural
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High postural sway (fourth quartile of ML sway)
Study: 30811685
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lowest bone density and highest postural sway
Study: 31721467
Drug: Dapagliflozin 5
Normalized name: dapagliflozin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 5 mg/day for 24 weeks
Study: 28460889
Drug: Olesoxime (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olesoxime (10 mg/kg per day)
Study: 26507206
Drug: Usual medical
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual medical treatment (tranexamic acid, mefenamic acid, combined oestrogen-progestogen or progesterone alone)